Global, regional, and national incidence of six major immune-mediated inflammatory diseases:

GBD 2019 IMID Collaborators

doi:10.1016/j.eclinm.2023.102193

Global, regional, and national incidence of six major immune-mediated inflammatory diseases:

GBD 2019 IMID Collaborators

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Background: The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. Methods: We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. Findings: In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of −0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = −0.41), inflammatory bowel disease (AAPC = −0.72), multiple sclerosis (AAPC = −0.26), psoriasis (AAPC = −0.77), and atopic dermatitis (AAPC = −0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. Interpretation: The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively. Funding: The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital ( 2022QN38).

Original language	English
Article number	102193
Journal	EClinicalMedicine
Volume	64
DOIs	https://doi.org/10.1016/j.eclinm.2023.102193
Publication status	Published or Issued - Oct 2023
Externally published	Yes

Keywords

Global burden of disease study
Immune-mediated inflammatory disease
Incidence
Trend

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.eclinm.2023.102193

Cite this

@article{52432bfe095140b7838663f8e983c254,

title = "Global, regional, and national incidence of six major immune-mediated inflammatory diseases:",

abstract = "Background: The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. Methods: We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. Findings: In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of −0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = −0.41), inflammatory bowel disease (AAPC = −0.72), multiple sclerosis (AAPC = −0.26), psoriasis (AAPC = −0.77), and atopic dermatitis (AAPC = −0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. Interpretation: The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively. Funding: The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital ( 2022QN38).",

keywords = "Global burden of disease study, Immune-mediated inflammatory disease, Incidence, Trend",

author = "{GBD 2019 IMID Collaborators} and Dongze Wu and Yingzhao Jin and Yuhan Xing and Abate, {Melsew Dagne} and Mohammadreza Abbasian and Mohsen Abbasi-Kangevari and Zeinab Abbasi-Kangevari and Foad Abd-Allah and Michael Abdelmasseh and Abdollahifar, {Mohammad Amin} and Abdulah, {Deldar Morad} and Aidin Abedi and Vida Abedi and Hassan Abidi and Aboagye, {Richard Gyan} and Hassan Abolhassani and Katrina Abuabara and Morteza Abyadeh and Addo, {Isaac Yeboah} and Adeniji, {Kayode Nelson} and Adepoju, {Abiola Victor} and Adesina, {Miracle Ayomikun} and Adnani, {Qorinah Estiningtyas Sakilah} and Mohsen Afarideh and Shahin Aghamiri and Antonella Agodi and Anurag Agrawal and Arriagada, {Constanza Elizabeth Aguilera} and Aqeel Ahmad and Danish Ahmad and Sajjad Ahmad and Sohail Ahmad and Ali Ahmadi and Ali Ahmed and Ayman Ahmed and Aithala, {Janardhana P.} and Ajadi, {Abdullateef Abiodun} and Marjan Ajami and Mostafa Akbarzadeh-Khiavi and Fares Alahdab and AlBataineh, {Mohammad T.} and Sharifullah Alemi and Al-Gheethi, {Adel Ali Saeed} and Liaqat Ali and Alif, {Sheikh Mohammad} and Almazan, {Joseph Uy} and Sami Almustanyir and Alqahtani, {Jaber S.} and Ibrahim Alqasmi and Gill, {Tiffany K.}",

note = "Funding Information: DZ Wu acknowledges support from Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38). A Ahmad acknowledges support from Shaqra University . A N Bhat acknowledges support from Kasturba Medical College, Mangalore, Manipal Academy of Higher Education. V B Bitra acknowledges support from the School of Pharmacy, University of Botswana. K Bora acknowledges support from the Indian Council of Medical Research (ICMR) under the research scheme titled {\textquoteleft}ICMR Capacity Building for Disease Estimation and Projection{\textquoteright} for the area Non-communicable Diseases. R Buchbinder is supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Fellowship. G Damiani acknowledges support from the Italian Center of Precision Medicine and Chronic Inflammation in Milan. A Fatehizadeh acknowledges support from the Department of Environmental Health Engineering of Isfahan University of Medical Sciences , Isfahan, Iran. V K Gupta acknowledges funding support from National Health and Medical Research Council (NHMRC), Australia. S Haque acknowledges support from Jazan University , Saudi Arabia for providing the access of Saudi Digital Library for this study. J Haubold acknowledges support from The Clinician Scientist Program of the Clinician Scientist Academy (UMEA) of the University Hospital Essen. N Ismail acknowledges support from AIMST University, Malaysia. N Joseph acknowledges the Department of Community Medicine , Kasturba Medical College, Mangalore , Manipal Academy of Higher Education, Manipal, India for their encouragement and support in this research work. H Kandel is supported by a Kornhauser Research Fellowship at The University of Sydney . J L{\'a}m acknowledges support from the National Research, Development and Innovation Office Hungary . K Latief acknowledges support from Taipei Medical University for Doctoral Education during the conduct of this review. G Liu was supported by CREATE Hope Scientific Fellowship from Lung Foundation Australia . A G Mathioudakis was supported by the National Institute for Health and Care Research Manchester Biomedical Research Centre and an NIHR Clinical Lectureship in Respiratory Medicine. J Padubidri acknowledges Kasturba Medical College, Mangalore and Manipal Academy of Higher Education, Manipal for their collaborative support for the research. A R Pathan acknowledges Author Gate Publications for their support. I Qattea acknowledges support from the Cleveland Clinic Foundation and Nassau University Medical center. A Raggi is supported by the Italian Ministry of Health (RRC). E M M Redwan acknowledges support from King Abdulaziz University (DSR), Jeddah, and King Abdulaziz City for Science & Technology (KACSAT), Saudi Arabia, Science & Technology Development Fund (STDF), and US-Egypt Science & Technology joint Fund : The Academy of Scientific Research and Technology ( ASRT ), Egypt. M Rodrigues was partially supported by the Centre of Studies in Geography and Spatial Planning. U Saeed would like to acknowledge the International Center of Medical Sciences Research (ICMSR), Islamabad Pakistan. A M Samy acknowledges the support from Ain Shams University and the Egyptian Fulbright Mission Program. A Schuermans was supported by the Belgian American Educational Foundation . A Sheikh acknowledges support from Health Data Research UK . R Tabar{\'e}s-Seisdedos is supported by the Spanish Ministry of Science and Innovation , Institute of Health Carlos III , CIBERSAM , and INCLIVA . S Tabatabaei would like to acknowledge the Clinical Research Development Unit , Imam Reza Hospital, Mashhad University of Medical Sciences, for their assistance. M Tabish would like to acknowledge Shaqra University for supporting this work. M R Tovani-Palone acknowledges Saveetha Institute of Medical and Technical Sciences and SRM Institute of Science and Technology for supporting this study. Sai Ullah acknowledges support by University of Agriculture, Faisalabad-Pakistan. Y Xing acknowledges support from the Chinese University of Hong Kong Research Committee Postdoctoral Fellowship Scheme. G Yahya acknowledges the institutional support of the Department of Microbiology and Immunology , Faculty of Pharmacy , Zagazig University, Egypt . A Zumla acknowledges support from the European (EU) and Developing Countries Clinical Trials Partnership , the EU Horizon 2020 Framework Programme , UK-National Institute for Health and Care Research , the Mahathir Science Award Foundation and EU-EDCTP. Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = oct,

doi = "10.1016/j.eclinm.2023.102193",

language = "English",

volume = "64",

journal = "EClinicalMedicine",

issn = "2589-5370",

publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Global, regional, and national incidence of six major immune-mediated inflammatory diseases:

AU - GBD 2019 IMID Collaborators

AU - Wu, Dongze

AU - Jin, Yingzhao

AU - Xing, Yuhan

AU - Abate, Melsew Dagne

AU - Abbasian, Mohammadreza

AU - Abbasi-Kangevari, Mohsen

AU - Abbasi-Kangevari, Zeinab

AU - Abd-Allah, Foad

AU - Abdelmasseh, Michael

AU - Abdollahifar, Mohammad Amin

AU - Abdulah, Deldar Morad

AU - Abedi, Aidin

AU - Abedi, Vida

AU - Abidi, Hassan

AU - Aboagye, Richard Gyan

AU - Abolhassani, Hassan

AU - Abuabara, Katrina

AU - Abyadeh, Morteza

AU - Addo, Isaac Yeboah

AU - Adeniji, Kayode Nelson

AU - Adepoju, Abiola Victor

AU - Adesina, Miracle Ayomikun

AU - Adnani, Qorinah Estiningtyas Sakilah

AU - Afarideh, Mohsen

AU - Aghamiri, Shahin

AU - Agodi, Antonella

AU - Agrawal, Anurag

AU - Arriagada, Constanza Elizabeth Aguilera

AU - Ahmad, Aqeel

AU - Ahmad, Danish

AU - Ahmad, Sajjad

AU - Ahmad, Sohail

AU - Ahmadi, Ali

AU - Ahmed, Ali

AU - Ahmed, Ayman

AU - Aithala, Janardhana P.

AU - Ajadi, Abdullateef Abiodun

AU - Ajami, Marjan

AU - Akbarzadeh-Khiavi, Mostafa

AU - Alahdab, Fares

AU - AlBataineh, Mohammad T.

AU - Alemi, Sharifullah

AU - Al-Gheethi, Adel Ali Saeed

AU - Ali, Liaqat

AU - Alif, Sheikh Mohammad

AU - Almazan, Joseph Uy

AU - Almustanyir, Sami

AU - Alqahtani, Jaber S.

AU - Alqasmi, Ibrahim

AU - Gill, Tiffany K.

N1 - Funding Information: DZ Wu acknowledges support from Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38). A Ahmad acknowledges support from Shaqra University . A N Bhat acknowledges support from Kasturba Medical College, Mangalore, Manipal Academy of Higher Education. V B Bitra acknowledges support from the School of Pharmacy, University of Botswana. K Bora acknowledges support from the Indian Council of Medical Research (ICMR) under the research scheme titled ‘ICMR Capacity Building for Disease Estimation and Projection’ for the area Non-communicable Diseases. R Buchbinder is supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Fellowship. G Damiani acknowledges support from the Italian Center of Precision Medicine and Chronic Inflammation in Milan. A Fatehizadeh acknowledges support from the Department of Environmental Health Engineering of Isfahan University of Medical Sciences , Isfahan, Iran. V K Gupta acknowledges funding support from National Health and Medical Research Council (NHMRC), Australia. S Haque acknowledges support from Jazan University , Saudi Arabia for providing the access of Saudi Digital Library for this study. J Haubold acknowledges support from The Clinician Scientist Program of the Clinician Scientist Academy (UMEA) of the University Hospital Essen. N Ismail acknowledges support from AIMST University, Malaysia. N Joseph acknowledges the Department of Community Medicine , Kasturba Medical College, Mangalore , Manipal Academy of Higher Education, Manipal, India for their encouragement and support in this research work. H Kandel is supported by a Kornhauser Research Fellowship at The University of Sydney . J Lám acknowledges support from the National Research, Development and Innovation Office Hungary . K Latief acknowledges support from Taipei Medical University for Doctoral Education during the conduct of this review. G Liu was supported by CREATE Hope Scientific Fellowship from Lung Foundation Australia . A G Mathioudakis was supported by the National Institute for Health and Care Research Manchester Biomedical Research Centre and an NIHR Clinical Lectureship in Respiratory Medicine. J Padubidri acknowledges Kasturba Medical College, Mangalore and Manipal Academy of Higher Education, Manipal for their collaborative support for the research. A R Pathan acknowledges Author Gate Publications for their support. I Qattea acknowledges support from the Cleveland Clinic Foundation and Nassau University Medical center. A Raggi is supported by the Italian Ministry of Health (RRC). E M M Redwan acknowledges support from King Abdulaziz University (DSR), Jeddah, and King Abdulaziz City for Science & Technology (KACSAT), Saudi Arabia, Science & Technology Development Fund (STDF), and US-Egypt Science & Technology joint Fund : The Academy of Scientific Research and Technology ( ASRT ), Egypt. M Rodrigues was partially supported by the Centre of Studies in Geography and Spatial Planning. U Saeed would like to acknowledge the International Center of Medical Sciences Research (ICMSR), Islamabad Pakistan. A M Samy acknowledges the support from Ain Shams University and the Egyptian Fulbright Mission Program. A Schuermans was supported by the Belgian American Educational Foundation . A Sheikh acknowledges support from Health Data Research UK . R Tabarés-Seisdedos is supported by the Spanish Ministry of Science and Innovation , Institute of Health Carlos III , CIBERSAM , and INCLIVA . S Tabatabaei would like to acknowledge the Clinical Research Development Unit , Imam Reza Hospital, Mashhad University of Medical Sciences, for their assistance. M Tabish would like to acknowledge Shaqra University for supporting this work. M R Tovani-Palone acknowledges Saveetha Institute of Medical and Technical Sciences and SRM Institute of Science and Technology for supporting this study. Sai Ullah acknowledges support by University of Agriculture, Faisalabad-Pakistan. Y Xing acknowledges support from the Chinese University of Hong Kong Research Committee Postdoctoral Fellowship Scheme. G Yahya acknowledges the institutional support of the Department of Microbiology and Immunology , Faculty of Pharmacy , Zagazig University, Egypt . A Zumla acknowledges support from the European (EU) and Developing Countries Clinical Trials Partnership , the EU Horizon 2020 Framework Programme , UK-National Institute for Health and Care Research , the Mahathir Science Award Foundation and EU-EDCTP. Publisher Copyright: © 2023 The Author(s)

PY - 2023/10

Y1 - 2023/10

N2 - Background: The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. Methods: We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. Findings: In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of −0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = −0.41), inflammatory bowel disease (AAPC = −0.72), multiple sclerosis (AAPC = −0.26), psoriasis (AAPC = −0.77), and atopic dermatitis (AAPC = −0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. Interpretation: The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively. Funding: The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital ( 2022QN38).

AB - Background: The causes for immune-mediated inflammatory diseases (IMIDs) are diverse and the incidence trends of IMIDs from specific causes are rarely studied. The study aims to investigate the pattern and trend of IMIDs from 1990 to 2019. Methods: We collected detailed information on six major causes of IMIDs, including asthma, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and atopic dermatitis, between 1990 and 2019, derived from the Global Burden of Disease study in 2019. The average annual percent change (AAPC) in number of incidents and age standardized incidence rate (ASR) on IMIDs, by sex, age, region, and causes, were calculated to quantify the temporal trends. Findings: In 2019, rheumatoid arthritis, atopic dermatitis, asthma, multiple sclerosis, psoriasis, inflammatory bowel disease accounted 1.59%, 36.17%, 54.71%, 0.09%, 6.84%, 0.60% of overall new IMIDs cases, respectively. The ASR of IMIDs showed substantial regional and global variation with the highest in High SDI region, High-income North America, and United States of America. Throughout human lifespan, the age distribution of incident cases from six IMIDs was quite different. Globally, incident cases of IMIDs increased with an AAPC of 0.68 and the ASR decreased with an AAPC of −0.34 from 1990 to 2019. The incident cases increased across six IMIDs, the ASR of rheumatoid arthritis increased (0.21, 95% CI 0.18, 0.25), while the ASR of asthma (AAPC = −0.41), inflammatory bowel disease (AAPC = −0.72), multiple sclerosis (AAPC = −0.26), psoriasis (AAPC = −0.77), and atopic dermatitis (AAPC = −0.15) decreased. The ASR of overall and six individual IMID increased with SDI at regional and global level. Countries with higher ASR in 1990 experienced a more rapid decrease in ASR. Interpretation: The incidence patterns of IMIDs varied considerably across the world. Innovative prevention and integrative management strategy are urgently needed to mitigate the increasing ASR of rheumatoid arthritis and upsurging new cases of other five IMIDs, respectively. Funding: The Global Burden of Disease Study is funded by the Bill and Melinda Gates Foundation. The project funded by Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital ( 2022QN38).

KW - Global burden of disease study

KW - Immune-mediated inflammatory disease

KW - Incidence

KW - Trend

UR - http://www.scopus.com/inward/record.url?scp=85172929794&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2023.102193

DO - 10.1016/j.eclinm.2023.102193

M3 - Article

AN - SCOPUS:85172929794

SN - 2589-5370

VL - 64

JO - EClinicalMedicine

JF - EClinicalMedicine

M1 - 102193

ER -

Global, regional, and national incidence of six major immune-mediated inflammatory diseases:

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this